HUMA
Humacyte, Inc.
Humacyte, Inc. insider trading
Humacyte, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent HUMA insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
HUMA insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded HUMA on the open market: 14 purchases worth $277.6K and 16 sales worth $18.8M, 2 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 2 purchases ($59.8K) and 5 sales ($3.8M), by 5 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | +$59.8K2 buys | −$82.6K2 sales · all on a plan | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | −$3.7M3 sales | |
| Q2 2025 | +$146.1K6 buys | — | |
| Q1 2025 | — | — | |
| Q4 2024 | +$36.2K3 buys | −$6.6M3 sales | |
| Q3 2024 | +$35.5K3 buys | −$8.4M8 sales |
- Largest purchase
- +$66K of HUMA by Sebelius Kathleen (Director) on Apr 08, 2025.
- Largest sale
- −$3.6M of HUMA by Niklason Laura E (President, CEO and Director) on Nov 18, 2024.
Open-market transactions through Jun 30, 2026most recent first
Sebelius Kathleen
Director
+$50K
May 19, 2026
56,818 sh · $0.88
Sander Dale A.10b5-1
CFO and Chief Corp. Dev. Off
−$41.3K
May 18, 2026
45,887 sh · $0.90
Parikh Shamik J10b5-1
Chief Medical Officer
−$41.3K
May 18, 2026
45,887 sh · $0.90
Constantino Michael T.
Director
+$9.8K
May 18, 2026
11,000 sh · $0.89
Dougan Brady W
Director
−$934.9K
Aug 20, 2025
591,685 sh · $1.58
Dougan Brady W
Director
−$1.8M
Aug 19, 2025
1,100,000 sh · $1.63
Dougan Brady W
Director
−$1M
Aug 18, 2025
549,360 sh · $1.83
Scheessele William John
Chief Commercial Officer
+$10K
Apr 14, 2025
6,493 sh · $1.54
Sander Dale A.
CFO and Chief Corp. Deve. Off.
+$30.6K
Apr 10, 2025
20,000 sh · $1.53
Parikh Shamik J
Chief Medical Officer
+$11.6K
Apr 10, 2025
7,500 sh · $1.55
Sebelius Kathleen
Director
+$66K
Apr 08, 2025
50,000 sh · $1.32
Green Charles Bruce
Director
+$7.7K
Apr 08, 2025
6,000 sh · $1.29
Constantino Michael T.
Director
+$20.2K
Apr 07, 2025
16,000 sh · $1.26
Constantino Michael T.
Director
+$20.2K
Dec 04, 2024
4,600 sh · $4.39
Niklason Laura E
President, CEO and Director
−$1.2M
Nov 20, 2024
261,369 sh · $4.40
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| May 19, 2026 | Sebelius KathleenDirector | 56,818 | $0.88 | +$50K |
| May 18, 2026 | Sander Dale A.10b5-1CFO and Chief Corp. Dev. Off | 45,887 | $0.90 | −$41.3K |
| May 18, 2026 | Parikh Shamik J10b5-1Chief Medical Officer | 45,887 | $0.90 | −$41.3K |
| May 18, 2026 | Constantino Michael T.Director | 11,000 | $0.89 | +$9.8K |
| Aug 20, 2025 | Dougan Brady WDirector | 591,685 | $1.58 | −$934.9K |
| Aug 19, 2025 | Dougan Brady WDirector | 1,100,000 | $1.63 | −$1.8M |
| Aug 18, 2025 | Dougan Brady WDirector | 549,360 | $1.83 | −$1M |
| Apr 14, 2025 | Scheessele William JohnChief Commercial Officer | 6,493 | $1.54 | +$10K |
| Apr 10, 2025 | Sander Dale A.CFO and Chief Corp. Deve. Off. | 20,000 | $1.53 | +$30.6K |
| Apr 10, 2025 | Parikh Shamik JChief Medical Officer | 7,500 | $1.55 | +$11.6K |
| Apr 08, 2025 | Sebelius KathleenDirector | 50,000 | $1.32 | +$66K |
| Apr 08, 2025 | Green Charles BruceDirector | 6,000 | $1.29 | +$7.7K |
| Apr 07, 2025 | Constantino Michael T.Director | 16,000 | $1.26 | +$20.2K |
| Dec 04, 2024 | Constantino Michael T.Director | 4,600 | $4.39 | +$20.2K |
| Nov 20, 2024 | Niklason Laura EPresident, CEO and Director | 261,369 | $4.40 | −$1.2M |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check HUMA — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Humacyte, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much HUMA stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 8 Humacyte, Inc. insiders made 14 open-market purchases worth $277.6K and 16 sales worth $18.8M. 2 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($59.8K) and 5 sales ($3.8M). The largest purchase was Sebelius Kathleen buying $66K on Apr 08, 2025. The largest sale was Niklason Laura E selling $3.6M on Nov 18, 2024.
- Where does HUMA insider trading data come from?
- From the Form 4 filings Humacyte, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.